乌鸦传媒

SUMMIT trial able to show clinical benefit beyond quality-of-life improvement

Researchers try to address challenge of distinguishing HCM from other cardiomyopathies

Evoque device helped outcomes in severe tricuspid regurgitation, with some safety caveats

Anti-mineralocorticoid agent reduced albuminuria, but not eGFR-based kidney outcome

Larger pool of TAVR candidates suggested by EARLY TAVR trial results

Effectiveness of this personalized approach now under investigation

Panelists acknowledge difficulty generating stronger data in ultra-rare disease

Benefit in symptoms, functional outcomes remains to be seen for HU6

Cardiac myosin inhibitor linked to improvements in biomarkers in small study

Vast majority of trial participants responded to aficamten

Benefit of the nonsteroidal MRA otherwise consistent across FINEARTS-HF

Meta-analysis holds LGE higher than LVEF in identifying high-risk NIDCM

Study lays out common gaps in evidence both before and after approval

Continued OAC failed to meet noninferiority in POPular PAUSE TAVI